cgen.com (CGEN) - Gross Sales Margin

Compugen Ltd. generates revenue from AI-driven drug target discovery, receiving royalties and upfront payments from Gilead. The business valuation relies on licensing unique immuno-oncology targets to pharma behemoths. Gross margin profitability reflects profit dynamics net of cost of sales, where 86.20 captures the current state of the parameter. The stable management of Anat Cohen-Dayag successfully monetizes intellectual property through strategic partnerships.
Analytical breakdowns and data insights for company Compugen Limited (CGEN)

An objective assessment of the investment attractiveness of Compugen Ltd. (CGEN) requires a deep analysis of direct cost management efficiency. Historical gross margin reflects the profit share after deducting the cost of goods sold, demonstrating the ability of the company's AI platform to optimize expenses while scaling its immuno-oncology portfolio. The stability of this metric confirms high capital density and the resilience of the B2B model during expansion into the global pharmaceutical market.